We are pleased to announce that Mark Beards has been appointed as CEO of Santero Therapeutics, effective immediately.
Mark joins us with extensive biotech leadership experience, having founded and led multiple life sciences companies in multiple therapy areas including the antibiotic space. His track record spans senior roles across life sciences (GSK, Abbott), advisory (McKinsey, Goldman Sachs) and Biotech (AMPLY Discovery, Cardiogeni, UTILITY therapeutics), with a particular focus on securing early-stage funding and operational delivery.
This appointment marks an exciting new chapter as we advance our mission to defeat multidrug-resistant infections through breakthrough RSH enzyme science. Our co-founder Cédric Govaerts transitions to Strategic Advisor, ensuring continuity of our scientific vision while Mark drives execution and our upcoming funding round.
"Mark brings exactly the blend of strategic rigour and operational experience we need as Santero moves from discovery into pre-clinical development," said Gokhan Batur, Santero's Chair. "This is the right leader at the right time."
The antimicrobial resistance crisis demands bold action. With our first-in-class platform, world-class science, and strengthened leadership, we're positioned to make a meaningful difference. Santero exists to end the era of untreatable infections.